Atheroregressive Potential of the Treatment with a Chimeric Monoclonal Antibody against Sulfated Glycosaminoglycans on Pre-existing Lesions in Apolipoprotein E-Deficient Mice
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2017.00782
Abstract: The retention of lipoprotein particles in the intima, in particular to glycosaminoglycan side chains of proteoglycans, is a critical step in atherosclerosis initiation. Administration of chP3R99, a chimeric mouse/human monoclonal antibody inducing an anti-idiotypic network… read more here.
Keywords: treatment; antibody; apolipoprotein deficient; mice ... See more keywords